Innovative Grade US Origin Swine Whole
To Order Contact us: lieven@wlsolutions.be
L-Tyrosine, USP grade, non-animal origin |
||
| GM1911-1KG | 1 kg | EUR 370.8 |
L-Tyrosine, USP grade, non-animal origin |
||
| GM1911-500G | 500 g | EUR 208.8 |
L-Glutamine, USP grade, non-animal origin |
||
| GM2001-1KG | 1 kg | EUR 370.8 |
Chondroitin sulfate, from bovine origin, USP grade |
||
| GC3554-50G | 50 g | EUR 217.2 |
Swine-Origin and Seasonal Flu H1N1 Protein Detection Set |
||
| PSI-1829 | 1 Set | EUR 1188.5 |
|
Description: Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin (4). The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups (5). Antibodies #5235 and 5239 are specific for the seasonal H1N1 influenza Hemagglutinin and will not recognize the corresponding Hemagglutinin sequence from the swine-origin H1N1 influenza (A/California/14/2009 (H1N1)). Similarly, antibodies #5237 and #5241 are specific for the swine-origin H1N1 influenza Hemagglutinin and will not recognize the seasonal H1N1 Hemagglutinin (A/Brisbane/59/2007 (H1N1). The Neuraminidase antibodies #5247 and #5249 are specific for seasonal and swine-origin H1N1 influenza Neuraminidase, respectively.;;For images please see PDF data sheet |
||
Insulin-US Standard F |
||
| F282F | 1 ml | EUR 234 |
|
Description: Insulin-US Standard F by Cygnus Technologies is available in Europe via Gentaur. |
||
Chitin, fungal origin |
||
| GC8934-1KG | 1 kg | EUR 220.8 |
Chitin, fungal origin |
||
| GC8934-250G | 250 g | EUR 97.2 |
Chitin, fungal origin |
||
| GC8934-500G | 500 g | EUR 141.6 |
Swine Elastase Antibody |
||
| 20271-05011 | 150 ug | EUR 260.4 |
Swine Albumin Antibody |
||
| 12004-05011 | 150 ug | EUR 260.4 |
Swine Haptoglobin Antibody |
||
| 15771-05011 | 150 ug | EUR 260.4 |
Swine Prothrombin Antibody |
||
| 25887-05011 | 150 ug | EUR 260.4 |
Goat Swine IgG |
||
| A21090-01ml | 0.1ml | EUR 92.4 |
|
Description: A polyclonal antibody for detection of Goat Swine IgG from Swine. This Goat Swine IgG antibody is for WB, IHC-P, ELISA. It is Affinity purified using solid phase Swine IgG (H&L) with finally > 95% purity based on SDS-PAGE and conjugated to HRP. The antibody is produced in goat by using as an immunogen Swine IgG whole molecule |
||
Goat Swine IgG |
||
| A21090-05ml | 0.5ml | EUR 189.6 |
|
Description: A polyclonal antibody for detection of Goat Swine IgG from Swine. This Goat Swine IgG antibody is for WB, IHC-P, ELISA. It is Affinity purified using solid phase Swine IgG (H&L) with finally > 95% purity based on SDS-PAGE and conjugated to HRP. The antibody is produced in goat by using as an immunogen Swine IgG whole molecule |
||
PIPET CONTROLLER BATTERY COVER (US VERSION) |
||
| 357487 | 1/pk | EUR 52.8 |
|
Description: Falcon Liquid Handling Equipment; Falcon Pipet Controllers and Accessories |
||
Insulin-US Standards Set, A-F |
||
| F282 | 1 ml | EUR 585.6 |
|
Description: Insulin-US Standards Set, A-F by Cygnus Technologies is available in Europe via Gentaur. |
||
Swine Swine Fever Virus Antibody (CSFV-Ab) ELISA Kit |
||
| abx364798-96tests | 96 tests | EUR 651.6 |
Mannide monooleate, animal origin |
||
| GC1955-100G | 100 g | EUR 217.2 |
Mannide monooleate, animal origin |
||
| GC1955-25G | 25 g | EUR 108 |
Cholesterol, non-animal origin |
||
| GE7110-1G | 1 g | EUR 274.8 |
Rat Whole Heart |
||
| PC35133 | P0 Rat - Whole Heart X2 | EUR 1341 |
Mouse Whole Heart |
||
| PC35135 | P0 Mouse - Whole heart X2 | EUR 1341 |
Histone (Whole) Antibody |
||
| abx023918-2ml | 2 ml | EUR 610.8 |
ProPette Pipette Controller, w/ QuickStand, 115V US |
||
| P6080 | 1/pack | EUR 230.9 |
|
Description: ProPette Pipette Controller w/ QuickStand |
||
Mini Dry Bath, 100-240V (US Plug) |
||
| BCM1405 | 1 pcs, 1 UNIT | EUR 473.48 |
12 Mini Centrifuge 100-240V (US plug) |
||
| BCM1746 | 1 pcs, 1 UNIT | EUR 680.54 |
Swine CCL2 Recombinant Protein |
||
| R00056-5 | 5ug/vial | EUR 259 |
|
Description: Chemokine (C-C motif) ligand 2 (CCL2), also known as monocyte chemotactic protein-1 (MCP-1), is a small cytokine belonging to the CC chemokine family. CCL2 (MCP-1) recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury and infection. Swine CCL2 (MCP-1) Recombinant Protein is purified CCL2 (MCP-1) produced in yeast. |
||
Swine CXCL10 Recombinant Protein |
||
| R00278-8 | 5ug/vial | EUR 259 |
|
Description: The ELR-negative CXC chemokine CXCL10 (IP-10) has been attributed to several roles, such as chemoattraction for monocytes/macrophages, T cells, NK cells, and dendritic cells, promotion of T cell adhesion to endothelial cells, antitumor activity, and inhibition of bone marrow colony formation and angiogenesis. Swine CXCL10 Recombinant Protein is purified CXCL10 (IP-10) produced in yeast. |
||
Swine EPO Recombinant Protein |
||
| R00484-2 | 5ug/vial | EUR 259 |
|
Description: Erythropoietin (EPO) is an essential hormone for red blood cell production. Erythropoietin has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers. Swine Erythropoietin Recombinant Protein is purified Erythropoietin (EPO) produced in yeast. |
||
Swine CCL5 Recombinant Protein |
||
| R00617-4 | 5ug/vial | EUR 259 |
|
Description: CCL5, also known as RANTES (regulated and normal T cell expressed and secreted), is a member of the C-C Chemokine Family. RANTES (CCL5) is chemotactic for T cells, eosinophils, and basophils, and plays an active role in recruiting leukocytes into inflammatory sites. Swine CCL5 Recombinant Protein is purified CCL5 (RANTES) produced in yeast. |
||
Swine CCL4 Recombinant Protein |
||
| R00703-7 | 5ug/vial | EUR 259 |
|
Description: The small chemotactic cytokine CCL4 (MIP-1 beta) is a chemoattractant for natural killer cells, monocytes and a variety of other immune cells. CCL4 is involved in several inflammatory and autoimmune diseases including viral infection such as HIV-1/AIDS. Swine CCL4 Recombinant Protein is purified chemokine ligand 4 (CCL4, MIP-1 beta) produced in yeast. |
||
Swine CCL20 Recombinant Protein |
||
| R00748-1 | 5ug/vial | EUR 259 |
|
Description: Chemokine ligand 20 (CCL20), also known as liver activation regulated chemokine (LARC) or Macrophage Inflammatory Protein-3 (MIP3A), is strongly chemotactic for lymphocytes. CCL20 elicits its effects on its target cells by binding and activating the chemokine receptor CCR6. Swine CCL20 Recombinant Protein is purified CCL20 (LARC, MIP3A) produced in yeast. |
||
Swine CD40LG Recombinant Protein |
||
| R01114-2 | 5ug/vial | EUR 259 |
|
Description: CD40 Ligand (CD40LG) is a transmembrane protein that is a member of the TNF superfamily. In addition to existing in a membrane bound form, CD40LG can also be released as a soluble molecule (sCD40LG), which has been shown to have biological functions.CD40 interacts with CD40 ligand (aka CD40LG, TNFSF5 or CD154), which is predominantly expressed on activated CD4+ T-cells. Swine CD40 Ligand Recombinant Protein is purified CD40LG produced in yeast. |
||
Swine BAFF Recombinant Protein |
||
| R01257-5 | 5ug/vial | EUR 259 |
|
Description: BAFF (B-cell Activation Factor), also known as Tumor Necrosis Factor Superfamily member 13B (TNFSF13B), is expressed in B cell lineage cells and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. Swine BAFF Recombinant Protein is purified b-cell activation factor produced in yeast. |
||
Swine CXCL9 Recombinant Protein |
||
| R01397-6 | 5ug/vial | EUR 259 |
|
Description: CXCL9 (MIG) is a T-cell chemoattractant. Induced by IFN-gamma (IFN-γ), the ELR-negative chemokine CXCL9 (MIG) elicits its effects by binding to the cell surface chemokine receptor CXCR3. Swine CXCL9 Recombinant Protein is purified CXCL9 (MIG) produced in yeast. |
||
Swine CXCL11 Recombinant Protein |
||
| R01833-1 | 5ug/vial | EUR 259 |
|
Description: Chemokine (C-X-C motif) ligand 11 (CXCL11) is a small, interferon-inducible cytokine belonging to the CXC chemokine family. Along with homologous ELR-negative CXC chemokines CXCL9 (MIG) and CXCL10 (IP-10), CXCL11 facilitates selective recruitment of mononuclear leukocytes, natural killer cells, and plasmacytoid dendritic cells to sites of inflammation. Swine CXCL11 Recombinant Protein is purified CXCL11 produced in yeast. |
||
Swine TWEAK Recombinant Protein |
||
| R02009-1 | 5ug/vial | EUR 259 |
|
Description: TNF-related weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor (TNF) ligand family (TNFSF12). TWEAK can induce apoptosis via multiple pathways of cell death in a cell type-specific manner. TWEAK is also found to promote proliferation and migration of endothelial cells, and thus acts as a regulator of angiogenesis. Swine TWEAK (TNFSF12) Recombinant Protein is purified TWEAK (TNFSF12) produced in yeast. |
||
Swine APRIL Recombinant Protein |
||
| R02417-5 | 5ug/vial | EUR 259 |
|
Description: A proliferation-inducing ligand (APRIL), also known as TNFSF13, is a member of the tumor necrosis factor (TNF) ligand superfamily. APRIL/TNFSF13 has been shown to play a role in protecting cells from undergoing apoptosis and promoting B cell development. Swine APRIL Recombinant Protein is purified APRIL (TNFSF13) produced in yeast. |
||
Swine CCL3L1 Recombinant Protein |
||
| R11820 | 5ug/vial | EUR 259 |
|
Description: CCL3L1, Chemokine (C-C motif) Ligand 3-Like 1, binds to several chemokine receptors including chemokine binding protein 2 (CCBP2) and CC chemokine receptor 5 (CCR5). Swine CCL3L1 Recombinant Protein is purified chemokine (C-C motif) ligand 3-like 1 produced in yeast. |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5233-002mg | 0.02 mg | EUR 206.18 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. This antibody is specific for the novel swine influenza Hemagglutinin and will not recognize the corresponding Hemagglutinin sequence from the seasonal H1N1 influenza (A/Brisbane/59/2007 (H1N1)). |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5233-01mg | 0.1 mg | EUR 523.7 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. This antibody is specific for the novel swine influenza Hemagglutinin and will not recognize the corresponding Hemagglutinin sequence from the seasonal H1N1 influenza (A/Brisbane/59/2007 (H1N1)). |
||
Swine H1N1 Hemagglutinin Peptide |
||
| 5233P | 0.05 mg | EUR 197.7 |
|
Description: Swine H1N1 Hemagglutinin peptide |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5237-002mg | 0.02 mg | EUR 206.18 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5237-01mg | 0.1 mg | EUR 523.7 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Hemagglutinin Peptide |
||
| 5237P | 0.05 mg | EUR 197.7 |
|
Description: Swine H1N1 Hemagglutinin peptide |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5241-002mg | 0.02 mg | EUR 206.18 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5241-01mg | 0.1 mg | EUR 523.7 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Hemagglutinin Peptide |
||
| 5241P | 0.05 mg | EUR 197.7 |
|
Description: Swine H1N1 Hemagglutinin peptide |
||
Swine H1N1 Neuraminidase Antibody |
||
| 5249-002mg | 0.02 mg | EUR 206.18 |
|
Description: Swine H1N1 Neuraminidase Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Neuraminidase Antibody |
||
| 5249-01mg | 0.1 mg | EUR 523.7 |
|
Description: Swine H1N1 Neuraminidase Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Neuraminidase Peptide |
||
| 5249P | 0.05 mg | EUR 197.7 |
|
Description: Swine H1N1 Neuraminidase peptide |
||
Swine/Rat Galanin Antibody |
||
| 10881-05011 | 150 ug | EUR 260.4 |
Swine H1N1 Hemagglutinin Antibody |
||
| 24918-100ul | 100ul | EUR 468 |
Swine H1N1 Hemagglutinin Antibody |
||
| 24920-100ul | 100ul | EUR 468 |
Swine H1N1 Hemagglutinin Antibody |
||
| 24922-100ul | 100ul | EUR 468 |
Swine H1N1 Neuraminidase Antibody |
||
| 24925-100ul | 100ul | EUR 468 |
Endothelin 1 (swine, human) |
||
| HY-P0202 | 500ug | EUR 258 |
Hyaluronidase Grade I (Molecular Biology Grade) |
||
| CE174 | 1 g | EUR 232.8 |
Hyaluronidase Grade I (Molecular Biology Grade) |
||
| CE175 | 5 g | EUR 920.4 |
alpha-Amanitin - fungal fermentation origin |
||
| ADC-P-107 | unit | Ask for price |
Calcium stearate, non-animal origin |
||
| GK5845-1KG | 1 kg | EUR 103.2 |
Calcium stearate, non-animal origin |
||
| GK5845-5KG | 5 kg | EUR 270 |
L-Cystine, non-animal origin |
||
| GM2911-100G | 100 g | EUR 93.6 |
L-Cystine, non-animal origin |
||
| GM2911-1KG | 1 kg | EUR 384 |
L-Cystine, non-animal origin |
||
| GM2911-250G | 250 g | EUR 150 |
L-Cystine, non-animal origin |
||
| GM2911-500G | 500 g | EUR 235.2 |
Chondroitin sulfate, from bovine origin |
||
| GC0982-1G | 1 g | EUR 51.6 |
Chondroitin sulfate, from bovine origin |
||
| GC0982-25G | 25 g | EUR 90 |
Chondroitin sulfate, from bovine origin |
||
| GC0982-50G | 50 g | EUR 132 |
Chondroitin sulfate, from bovine origin |
||
| GC0982-5G | 5 g | EUR 62.4 |
Monkey IgM (whole molecule) |
||
| 31R-AI093 | 250 µg | EUR 500.4 |
|
Description: Monkey whole IgM |
||
Whole Human Serum antibody |
||
| 20-1727 | 1 L | EUR 36 |
|
Description: Goat polyclonal Whole Human Serum antibody |
||
Whole Human Serum antibody |
||
| 20-S1110G000-V0 | 10 ml | EUR 159.6 |
|
Description: Goat polyclonal Whole Human Serum antibody |
||
CMV protein (whole cell) |
||
| 30-AC70 | 1 ml | EUR 483.6 |
|
Description: Purified native CMV protein (whole cell) |
||
Whole Blood PCR Mix |
||
| M1143-200 | EUR 321 | |
Mixer Heated Plate Vortexer 115-240V (US Plug) |
||
| BCM1630 | 1 pcs, 1 UNIT | EUR 2412.46 |
Pig/Swine Anti-African Swine fever virus (ASFV) IgG negative control serum |
||
| RV-500900-01N | 1 ml | EUR 164 |
Pig/Swine Anti-African Swine fever virus (ASFV) IgG positive control serum |
||
| RV-500900-02P | 1 ml | EUR 225 |
Rabbit Anti-Pig/Swine Anti-African Swine fever virus (ASFV) IgG antiserum |
||
| ASFV11-S | 100 ul | EUR 548.4 |